238 related articles for article (PubMed ID: 31445964)
1. Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.
Guo Z; Cui W; Que L; Li C; Tang X; Liu J
Int J Oral Maxillofac Surg; 2020 Mar; 49(3):298-309. PubMed ID: 31445964
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience.
Taş Ozyurtseven B; Serin I; Nursal AF; Pehlivan S; Pehlivan M
BMC Oral Health; 2021 May; 21(1):272. PubMed ID: 34006261
[TBL] [Abstract][Full Text] [Related]
3. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
4. Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis.
Yao S; Ding X; Rong G; Zhou J; Zhang B
J Craniofac Surg; 2023 Mar-Apr 01; 34(2):669-673. PubMed ID: 36184756
[TBL] [Abstract][Full Text] [Related]
5. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
6. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis.
Zhong DN; Wu JZ; Li GJ
Acta Haematol; 2013; 129(2):90-5. PubMed ID: 23171856
[TBL] [Abstract][Full Text] [Related]
8. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
9. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
10. Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Wazzan T; Kashtwari D; Almaden WF; Gong Y; Chen Y; Moreb J; Katz J
Spec Care Dentist; 2018 Nov; 38(6):356-361. PubMed ID: 30194738
[TBL] [Abstract][Full Text] [Related]
11. [Research progress in the treatment and prevention of medication-related osteonecrosis of the jaw].
Xu LC; Li YF
Zhonghua Kou Qiang Yi Xue Za Zhi; 2020 Jul; 55(7):509-514. PubMed ID: 32634892
[TBL] [Abstract][Full Text] [Related]
12. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.
Cavalcante RC; Tomasetti G
J Craniomaxillofac Surg; 2020 Nov; 48(11):1080-1086. PubMed ID: 32998853
[TBL] [Abstract][Full Text] [Related]
13. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
Schoenhof R; Munz A; Yuan A; ElAyouti A; Boesmueller H; Blumenstock G; Reinert S; Hoefert S
J Craniomaxillofac Surg; 2021 Jun; 49(6):508-517. PubMed ID: 33707134
[TBL] [Abstract][Full Text] [Related]
14. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
15. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
16. A population based study of multiple myeloma patients with medication-related osteonecrosis of the jaw.
Auzina D; Slaidina A; Sevastjanova M; Erts R; Lejnieks A; Lejniece S
Stomatologija; 2019; 21(1):13-17. PubMed ID: 31619658
[TBL] [Abstract][Full Text] [Related]
17. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
Zhao N; Li QX; Wang YF; Qiao Q; Huang HY; Guo CB; Guo YX
BMC Oral Health; 2023 May; 23(1):330. PubMed ID: 37245004
[TBL] [Abstract][Full Text] [Related]
19. The assessment of halitosis with a new screening tool in medication-related osteonecrosis of the jaw.
Choi Y; Kim J; Rhee Y; Park JH; Nam W; Park W
Clin Oral Investig; 2024 Jan; 28(1):102. PubMed ID: 38233664
[TBL] [Abstract][Full Text] [Related]
20. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
